CAMP4 Therapeutics
CAMP
40 hedge funds and large institutions have $235M invested in CAMP4 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
177% more capital invested
Capital invested by funds: $84.6M → $235M (+$150M)
38% more funds holding
Funds holding: 29 → 40 (+11)
21.41% more ownership
Funds ownership: 60.17% → 81.58% (+21%)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.06M |
| 3 |
Janus Henderson Group
London,
|
+$7.09M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.78M |
| 5 |
BlackRock
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ES
Enavate Sciences
Menlo Park,
California
|
-$3.19M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.96M |
| 3 |
Millennium Management
New York
|
-$361K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22.3K |
| 5 |
Two Sigma Investments
New York
|
-$12.1K |
CAMP Hedge Fund Activity: Q4 2025 in Review
40 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in CAMP4 Therapeutics (CAMP) for Q4 2025, worth a combined $235M — up 177% from $84.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CAMP positions and 2 closed out — a net gain of 11 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $10.4M. The largest seller was Enavate Sciences, cutting an estimated $3.19M.
- 40 institutional investors held CAMP4 Therapeutics (CAMP) as of Q4 2025, up from 29 in Q3 2025.
- Funds reported $235M of CAMP4 Therapeutics stock for Q4 2025, up 177% quarter-over-quarter.
- 13 funds opened new CAMP4 Therapeutics positions in Q4 2025 and 2 closed out, a net change of +11 holders.
- The largest CAMP4 Therapeutics buyer in Q4 2025 was Balyasny Asset Management, an estimated $10.4M added.
- The largest CAMP4 Therapeutics seller in Q4 2025 was Enavate Sciences, an estimated $3.19M sold.
Based on aggregated 13F filings for Q4 2025.